NCT00608985
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
See it on ClinicalTrials.gov ↗707 people
61.7%
38.3%
436 womenmiddle line = equal numbers271 men
- Phase
- PHASE3
- Paid for by
- Midnight Pharma, LLC
- Finished
- 2009-11
- Health conditions
- Primary Insomnia
- Who could join
- Anyone
- Ages
- 18 Years – 64 Years
- Average age
- mean 45.4 years
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 64 Years.”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“History of any sleep disorder, or any Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) axis I disorder other than primary insomnia.”
- No smokers
Women who smoke or use nicotine were turned away.
“Important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2 years prior to the screening visit.”
Study titles and rules are shown in their original English.